Loading Events

« All Events

  • This event has passed.

The Ketamine Conference – A Molecular Masterclass [ONLINE]

August 21 - August 22



Deep dives into key psychedelic compounds.

21st & 22nd August 2020

Ketamine is creating new pathways to pain management and better mental health. We present a complete exploration of ketamine at the intersection of clinical care, research and investment, featuring the world’s top researchers, clinicians, companies, advocates and experts.

Discover the potential of ketamine and NMDA receptor antagonists in the treatment of key mental and physical conditions through keynote presentations, expert panels, interactive discussions and collaboration. This two-day conference brings together experts in the field to discuss the very latest science, health care innovation and business opportunities in this rapidly growing field.


  • Ketamine Media – a global leader in helping providers raise awareness about the clinical use of ketamine.
  • Alan Aldous – a cannabis & psychedelics PR firm providing public relations transparency to the world of emerging markets.
  • Microdose – psychedelic insights, events, content, and market intelligence.
  • Psyindex is a media partner with the leading psychedelics index, powered by CFN Enterprises Inc. (OTCQB: CNFN).


Jeffrey Becker, MD

Chief Scientific Officer, Bexson Biomedical

Dr. Becker has over 20 years of research and clinical experience in NMDA-receptor pharmacology and clinical use and is a world-recognized speaker and expert in the neurobiology and clinical use of ketamine.


Martha B. Koo, MD

Founder and Medical Director, Neuro Wellness Spa

Dr. Martha B. Koo, M.D., completed her undergraduate studies at Princeton University, where she graduated Magna Cum Laude, and her medical training at the David Geffen School of Medicine at UCLA, where she earned membership to the AOA and Sigma Xi Society for academic excellence.

Steve Mandel, MD

Founder and President, Ketamine Clinics of Los Angeles

As a world-renowned pioneer in the use of Ketamine Infusion Therapy to treat depression, suicidality, PTSD, and chronic pain conditions, Dr. Mandel has appeared on television, radio, podcasts, and in numerous publications including The Doctors, CBS, PBS, VICE, Inc Magazine, BuzzFeed, Wired, and LA Magazine.

Veronika Gold, MFT

Co-Founder, Therapist, CEO, Polaris Insight Center

Veronika Gold is the co-founder and CEO of Polaris Insight Center in San Francisco, a clinic providing Ketamine Assisted Psychotherapy treatment for depression, anxiety, PTSD, and other mental health issues.


Wes Ryan, MD

Psychiatrist and Psychotherapist, Wesley Ryan MD PC

Dr. Ryan is a psychiatrist and psychotherapist based in Los Angeles with additional fellowship training in addiction psychiatry, and specializing in consultations regarding psychedelics as well as the use of ketamine assisted psychotherapy.

Anthony El Chibani

Managing Partner, Ketamine Media

During his senior year at the University of Tennessee, Anthony joined Ketamine Media. His responsibilities as Managing Partner include overseeing internal and external company relationships, sparking innovation, creativity, helping to fuel the growth of Ketamine Media, and raise awareness for the industry as a whole.

David Feifel

Director, Kadima Neuropsychiatry Institute

Dr. Feifel is a Professor Emeritus at University of California San Diego and a pioneer in treating mental illness with Ketamine. In 2008 he established at UCSD, the first clinical program in the world to offer ketamine infusions for psychiatric disorder. He Director of Kadima Neuropsychiatry Institute, a private institute in La Jolla, California, focusing on innovative treatments such as ketamine and other psychedelic drugs for mental illness. Among his ongoing projects at Kadima, he is overseeing several clinical trials of psilocybin for psychiatric disorders.

Gregg Peterson

CEO, Bexson Biomedical

Gregg has over 20 years of experience developing pharmaceutical, medical device, biologic and combination products, leading the commercial launch of over a dozen products globally. He was previously a Global R&D Program Lead for an S&P500 company with a focus on US, EU and AsiaPac.

Sandhya Prashad

Medical Director, Houston Ketamine Therapeutics

Sandhya Prashad, MD is a board-certified psychiatrist and is the founder and medical director of Houston Ketamine Therapeutics and Houston TMS Therapeutics. She has been administrating IV Ketamine in her practice since 2016 and is also a founding member, the former secretary and the current president of the American Society of Ketamine Physicians.

Stephen Parker

Certified Ketamine Infusion Specialist/Doctor of Anesthesia Practice (DrAP)/Certified Registered Nurse Anesthetist (CRNA), Life Infusions, LLC

Doctor of Anesthesia Practice (DrAP/CRNA) and anesthesia clinician/researcher for more than 13 years with expertise in the areas of paediatric emergence delirium and pain management, Ketamine administration and therapies (including pain management, psychiatric applications, and anesthesia utilization), and opioid-free anesthetic techniques, including total intravenous anesthetics (TIVA).

Steve Best

Director, The Neuroscience Center

Steve Best, M.D. is Certified in Psychiatry, and completed a 2-year sub-specialty Fellowship in Neuropsychiatry of Children and Adults at Chicago Medical School. During his fellowship he was also trained in the application of functional brain imaging (PET) to Neuropsychiatry.

Itai Danovitch, MD, MBA

Chairman of the Department of Psychiatry and Behavioral Neurosciences, Cedars-Sinai Medical Center

Dr. Danovitch is the Chairman of the Department of Psychiatry and Behavioral Neurosciences at Cedars-Sinai Medical Center in Los Angeles. His research is focused on the treatment of substance use disorders and the integration of medical and mental health services.

Jenny Southgate, PhD

Director of Jack Birch Unit and Professor of Molecular Carcinogenesis, University of York

Jennifer Southgate trained at the Imperial Cancer Research Fund (ICRF) in London and has a PhD in epithelial cell and cancer biology from the Department of Medicine, University of Leeds.

Nadiv Samimi, MD

Medical Director, Pain & Healing Institute

Nadiv is a pain management physician from Los Angeles, providing private and concierge care for patients suffering from chronic pain disorders, mood disorders and providing guidance on maintaining a healthy body.

Brent Turnipseed, MD

Founder, Medical Director, Roots Behavioral Health

Brent Turnipseed is a co-founder and Medical Director of Roots Behavioral Health. Under Brent’s leadership, clinicians at Roots have been able to offer integrative psychiatric care to over 5,000 central Texans. Additionally, Brent helped to create a ketamine-assisted psychotherapy program in 2018, the first of its kind in Austin.

Michael Boyko

Partner, The Grow To

Michael helps Ketamine providers and clinics across the US with digital marketing efforts.

Samuel Ko, MD, MBA

MD, Medical Director & Founder, Reset Ketamine – Palm Springs

Dr. Samuel Ko is a Board Certified Emergency Physician and medical director of Reset Ketamine. He is a Fellow of the American College of Emergency Physicians and member of the American Society of Ketamine Physicians.

Scott Shannon

Chief Medical Officer, Psychedelic Research and Training Institute

Scott serves as a site Principle Investigator and therapist for the Phase II and the Phase III trial of MDMA assisted psychotherapy for PTSD sponsored by Multidisciplinary Association for Psychedelic Studies (MAPS).

Rupert McShane, MD

Associate Professor, University of Oxford

Rupert is a consultant psychiatrist and associate professor working in Oxford UK.  Following an NIHR funded case series study of ketamine infusions, he has treated over 300 patients with TRD, more recently using a combination of monthly IV and weekly oral dosing.

Jason Wallach, PhD

Director, Bexson Discovery

Dr. Jason Wallach obtained his PhD in Pharmacology and Toxicology from the University of the Sciences, where he is also currently an associate professor in the Department of Pharmaceutical Sciences. Dr. Wallach also has an appointment to the Substance Use Disorders Institute at University of the Sciences and an adjunct appointment at Cooper Medical School of Rowan University where he teaches pathology, pharmacology and biochemistry courses. He also advises pharmaceutical companies in drug development and is the director of discovery at Bexson Biomedical.

Jennifer Winegarden, DO

Medical Director, The Medical Team Hospice

Dr. Jennifer Winegarden, D.O., M.S. graduated from Michigan State University College of Osteopathic Medicine and is board certified in Family Medicine and Hospice and Palliative Medicine. She holds a master’s degree in Pain Research, Education and Policy from Tufts University. She has extended education in the field of neurology and pharmacology which has fueled her interest in the treatment of pain, and the use of adjuvant pain medications. This has included significant research in the use of non-opioid medications, particularly ketamine, to better control pain while reducing the need for opioid medications.

Jesse Gould

Heroic Hearts Project

Jesse Gould is a pioneer in psychedelic therapies. As Founder and President of the Heroic Hearts Project, he has spearheaded the research and acceptance of ayahuasca therapy programs for military veterans. Jesse has raised over $150,000 in scholarships and his mission is to help military veterans struggling with mental trauma and spread awareness of the benefits that ayahuasca therapies offer as an alternative treatment to pharmaceuticals.

Jon Wolfe

CEO, Austin Ketamine Clinic

After spending almost fifteen years working on Austin’s elite special operations rescue team, my partner and I founded Austin Ketamine Clinic to better serve Austin’s mental health needs of the community striving to help make ketamine therapy more accessible and affordable. My education includes an AAS in Emergency Medical Services from Austin Community College, a BS in Emergency Medical Services from UT Health Science Center at San Antonio and a MPA in Emergency Management from Anna Maria College.


Lowan Stewart, MD FAAEM

Medical Director, AxonKlinikken

Dr. Stewart´s opened the first ketamine treatment clinics in both New Mexico and Scandinavia, and has done over two thousand ketamine treatments for a variety of conditions. In Oslo, he set up the research group PsykForsk (the center for innovative treatment in mental health) for the development of psychedelic treatments for depression, PTSD and addiction. He is currently working on clinical trials with MDMA for PTSD (MAPS), psilocybin for depression (COMPASS), esketamine (Janssen) and ketamine for suicidal ideation and death anxiety. He serves on the editorial board of the Journal of Psychedelic Studies and is the co-founder of the Norwegian Association for Psychedelic Science.

Lucia Huang

Co-founder and CEO, Osmind

Lucia is co-founder and CEO of Osmind. She is a graduate of Yale and earned an MBA at Stanford Graduate School of Business, where she was also awarded a Certificate in Public Management and Social Innovation. At Stanford, Lucia focused her studies on healthcare and co-led the GSB Healthcare Club. Lucia is passionate about mental health and has devoted her entire career to improving healthcare, from life sciences to new technology innovation. She was most recently working to help cure ALS and Parkinson’s at a neuroscience biotechnology company. She previously invested in innovative healthcare technology companies.


Megan Oxley, MD

Medical Director, Michigan Progressive Health

Dr. Megan Oxley is a board certified emergency medicine physician and the founder and medical director of Michigan Progressive Health, an integrative ketamine infusion clinic. She is a founding board member of the American Society of Ketamine Physicians, Psychotherapists and Practitioners and the current Vice President. She has organized the ASKP3 conferences for the last three years and has been a speaker at ASKP3, KRIYA and several Universities in Michigan.


Phil Wolfson, MD

CEO and Founder, Ketamine Reserach Foundation/Progressive Therapeutics/Awakened Medicine Foundation

Phil Wolfson MD is the creator of a new psychotherapy modality based on use of the medicine ketamine—Ketamine Assisted Psychotherapy (KAP). Phil is the CEO of the non-profit Ketamine Research Foundation and directs the training of KAP practitioners through The Ketamine Training Center. He is the author of The Ketamine Papers and Noe – A Father/Son Song of Love, Life, Illness and Death. He has been the Principal Investigator of the recently completed MAPS.org Phase 2 study of MDMA treatment for individuals with life-threatening illnesses. He is a Founder of Progressive Therapeutics Inc and CEO of the newly formed Awakened Medicine Foundation. He has created 7 patents for unique herbal medicines and ketamine. Phil was a founding member of the Heffter Research Institute. He is a graduate of Brandeis University and NYU School of Medicine.


Raj Mehra, PhD

Chairman and CEO, Seelos Therapeutics

Dr. Raj Mehra is the Chief Executive Officer, Director and Founder of Seelos. Prior to founding Seelos, Dr. Mehra spent nine years at Auriga USA, LLC as a Managing Director focused on private and public equity investments in global healthcare companies. Prior to Auriga, Dr. Mehra was the sector head for healthcare equity investments at Bennett Lawrence Management, LLC in New York. He also founded and managed a long-short equity hedge fund at Weiss, Peck & Greer LLC. Dr. Mehra started his career as an investment professional at Cowen Asset Management, LLC. Dr. Mehra holds M.S., M.Phil., Ph.D., JD and MBA degrees from Columbia University in New York. He is also a graduate of Indian Institute of Technology, Kanpur, where he was ranked first in his class.

Rupert McShane, MD

Associate Professor, University of Oxford

Rupert is a consultant psychiatrist and associate professor working in Oxford UK.  Following an NIHR funded case series study of ketamine infusions, he has treated over 300 patients with TRD, more recently using a combination of monthly IV and weekly oral dosing.  He runs the NHS ECT service for Oxfordshire and chairs the Royal College of Psychiatrists ECT and Related Treatments Committee.   He organised the first international ketamine conference in Oxford in 2018 and is organising a repeat hybrid online (N=as many as are interested) and in-person (N=120) conference for late March 2021.


Will Van Derveer, MD

Medical Director, Integrative Psychiatry Centers

In addition to medically directing the Integrative Psychiatry Center in Boulder, CO, he is co-founder, with Keith Kurlander, of the Integrative Psychiatry Institute, www.psychiatryinstitute.com. Dr. Van Derveer has published research on MDMA-assisted psychotherapy for PTSD [1] and written book chapters in the fields of ketamine-assisted psychotherapy and other clinical applications of psychedelic compounds. In addition to traditional medical training, He is a meditation instructor and has trained in shamanism, EMDR, somatic experiencing, internal family systems, cognitive behavioral therapy, and hypnosis. The IPC clinic protocols are based on his synthesis of a wide range of treatment approaches, and over two decades of practicing and teaching other doctors this holistic approach.


Zappy Zapolin

Conscious Filmmaker, The Mind Army

Zappy won the Amsterdam Film Festival’s Van Gogh award for his film The Reality Of Truth. The film is a cult classic in the “Plant Medicine” genre and features actress Michelle Rodriguez, Deepak Chopra, Marianne Williamson, Ram Dass, and Joel Osteen. Zappy is the Founder of the Mind Army social movement which is Fighting For The Right to Pursue Happiness. Zappy is a Co-Founder with Warren Gumpel of the Ketamine Fund a 501(c)3 which has donated more than 400 free treatments to veterans suffering from PTSD.


Alana Armstrong

Co-Founder, Alan Aldous Communications

Alana Armstrong is one fifth of the concoction called Alan Aldous Communications, bringing 11+ years of journalism to its cognitively diverse table. Alana has spent most of the past five years researching and reporting on the cannabis industry, and when she’s not reading or writing about drugs, she’s probably in the garden growing her own.


Julane Andries, MFT

LMFT lead KAP therapist, officer on board of KRF, researcher MAPP 2 (MAPS MDMA FOR PTSD) Ketamine Research Foundation, Center for Transformational Psychotherapy

Julane Andries LMFT is a practicing psychotherapist in Marin County, Ca. She worked in acute care medicine before becoming a Marriage Family Therapist, graduating from Dominican University. She was the principle co-therapist for the completed MAPS sponsored, FDA approved, Phase 2 MDMA assisted psychotherapy study for individuals suffering from anxiety with life-threatening illness. She is also a clinical researcher in the MAPS sponsored Phase 3 study using MDMA assisted psychotherapy for PTSD. In her work with Ketamine Assisted Psychotherapy, she has been a pioneer in its development and application through The Center for Transformational Psychotherapy. Julane has a clinical practice using Kap; she also helps lead trainings teaching the principles and experiencer of Kap to practitioners. She is involved in research through KRF- and has particular interest in using ketamine for PMS and post-partum depression, as well as use of ketamine for those with life threatening illness and end of life.


Kelan Thomas, PharmD

Associate Professor & Psychiatric Pharmacist, Touro University California

Kelan is an Associate Professor and Board Certified Psychiatric Pharmacist with outpatient behavioral health practice sites in San Francisco and Oakland. His research interests include adverse reactions and drug interactions related to psychiatric medications and psychedelic-assisted therapy.


Will Siu, MD


Will Siu, MD, DPhil, completed medical and graduate school at UCLA and the University of Oxford, respectively, before training as a psychiatrist at Harvard Medical School. He remained on the faculty at Harvard for two years prior to moving to New York City and later Los Angeles to further pursue his interest in psychedelic medicine as a practitioner and public advocate through speaking, writing, and social media.


Dr. Daniel Richman, MD

Anesthesiologist & Physician, Hospital for Special Surgery in the Department of Anesthesiology, Critical Care & Pain Management

Dr. Richman has extensive knowledge of managing advanced pain with implantable technology such as intrathecal pumps and spinal cord stimulators. He frequently works with both the inpatient and outpatient pain divisions within the HHS as an expert in managing difficult perioperative analgesia in the chronic pain patient.


Reid Robinson, MD, MBA

Medical Director, Cedar Psychiatry

Reid Robison, MD MBA, is a board-certified psychiatrist who has led over 100 clinical trials in neuropsychiatry. Reid is co-founder at Cedar Psychiatry, and serves as Medical Director of Center for Change, a top Eating Disorder program. He is currently the coordinating investigator for the MAPS MDMA-assisted Psychotherapy study of Eating Disorders.


Patrick Moher

Partner, Microdose

Patrick is the founder of Ethical Image and a partner at Microdose. As a passionate and unapologetic environmentalist, Patrick’s relentless work ethic is focused on helping brands combine profit, image, and social responsibility. His ability to unite people enables unique business solutions. which has seen him co-found Alan Aldous Communications, UCannAcademy, and Goodwood Accessories, and recently become a partner at ADCANN. He’s also served as a leader with multiple volunteer organizations, documented over 500 events as a photographer, and sponsored 20,000 tree plantings (and counting).


Abid Nazeer MD, FASAM

President and Medical Director, APS Ketamine

Dr. Nazeer is board certified in Psychiatry as well as Addiction Medicine and in 2016 had established the first psychiatric outpatient ketamine clinic in Illinois. Dr. Nazeer is the Chief Medical Officer for Symetria Recovery, a comprehensive opioid treatment center, overseeing their current 13 locations nationally.


Nicolas Grundmann, MD

Founder, Ember Health

Dr. Grundmann pursued his residency training at Kings County Hospital / SUNY Downstate in Brooklyn, NY, and received his Medical Degrees and Masters in Business Administration from Stanford University. He lives in Brooklyn with his wife and family. Nico founded Ember Health as a way to help individuals take control of their lives, and contribute to the shaping of a field in line with his values.


Gita Vaid, MD

Psychiatrist & Psychoanalyst

Gita Vaid, MD is a Board Certified Psychiatrist and Psychoanalyst practicing in New York City. Dr Vaid completed her residency training at NYU Medical Center and psychoanalytic training at the Psychoanalytic Association of New York.


David Lodge, PhD

Professor Emeritus, University of Bristol

David demonstrated that ketamine selectively blocked NMDA receptors and excitatory synaptic transmission. He also correlated NMDA antagonism with PCP-like dissociative activity of established and newly developed psychedelic compounds.


Josh Lawler

Partner, Zuber Lawler

Josh Lawler leads the finance and mergers and acquisitions practice groups at Zuber Lawler. Headquartered in Los Angeles, Zuber Lawler is a minority-owned national law firm specializing in high stakes complex business matters, including finance, mergers and acquisitions, and corporate governance.


Tatiana Santini

Ketamine Assisted Therapist, Field Trip

Tatiana is a Ketamine Assisted Therapist at Field Trip Health. She completed a post-graduate certificate in Psychedelic Assisted Therapies and Research at CIIS, including MDMA assisted psychotherapy, and she has completed Ketamine Assisted Psychotherapy (KAP) training with Dr. Phil Wolfson and Ketamine Training Center.


Jonathan Sporn, MD

CEO, Gilgamesh Pharmaceuticals

Dr. Sporn is a Board Certified Psychiatrist educated and trained at Duke, Univ of Miami, Tufts, The Boston Psychoanalytic Institute, Harvard University, and the National Institutes of Health. After practicing psychiatry in Boston where he was Chief of Psychiatry at a community Hospital, he worked as a Clinic Director at Boston University, and did research at The Mass. General Hospital.


Warren Gumpel

Owner, The Ketamine Fund


Rachel Aidan, Ph.D.c

Synthesis Retreat




The Conscious Fund